IRUBIS on LinkedIn: IRUBIS Press Release | Munich, DE, August 2024 | 22 comments

Funding Rounds

▤ Summary

\U0001f389 - another milestone towards calibration model-free PAT in upstream! Were beyond excited to share our new publication \U0001f4d1 with Amgen Research (Munich) GmbH, Automized inline monitoring in perfused mammalian cell culture by MIR spectroscopy without calibration model building, diving into our cutting-edge Process Analytical Technology (#PAT), #Monipa, used successfully for the prediction of glucose and lactate concentrations in mammalian cell perfusion (PER) processes. \U0001f9ea We would like to extend our thanks to the authors for their great efforts and express gratitude for the dynamic collaboration! \U0001f64c \U0001f4a5Now discover the publication here: https://lnkd.in/dEWAJmnz As we are about to turn the page to a new year, we continue our commitment to innovation and excellence in bioprocessing! \U0001f447 \U0001f4e8 Schedule a meeting via monipa@irubis.com irubis.com/monipa #innovation #spectroscopy #bioprocessing #USP #DSP

$ Funding

$
Amount - Total raised
□
Date August 29, 2024 Announcement date
◎
Investors - Lead investors
▥
Company https://irubis.com/ Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies

Refresh Inc.
$1M to $5M